<?xml version="1.0" encoding="UTF-8" standalone="no"?><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:in-capmkt="https://www.sebi.gov.in/xbrl/2022-12-31/in-capmkt" xmlns:in-capmkt-ent="https://www.sebi.gov.in/xbrl/Regulation_30_Restructuring/2022-12-31/in-capmkt/in-capmkt-ent" xmlns:in-capmkt-roles="https://www.sebi.gov.in/xbrl/Regulation_30_Restructuring/2022-12-31/in-capmkt-roles" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink"><link:schemaRef xlink:href="in-capmkt-ent-2022-12-31.xsd" xlink:type="simple"/><xbrli:context id="OneI"><xbrli:entity><xbrli:identifier scheme="https://www.sebi.gov.in/in-capmkt/ISIN">544122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="OneD"><xbrli:entity><xbrli:identifier scheme="https://www.sebi.gov.in/in-capmkt/ISIN">544122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-28</xbrli:startDate><xbrli:endDate>2025-05-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="INR"><xbrli:measure>iso4217:INR</xbrli:measure></xbrli:unit><xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><in-capmkt:NameOfTheCompany contextRef="OneI">ENTERO HEALTHCARE SOLUTIONS LIMITED</in-capmkt:NameOfTheCompany><in-capmkt:NSESymbol contextRef="OneI">ENTERO</in-capmkt:NSESymbol><in-capmkt:TypeOfAnnouncementPertainingToRegulation30Restructuring contextRef="OneD">New</in-capmkt:TypeOfAnnouncementPertainingToRegulation30Restructuring><in-capmkt:EventOfAnnouncementPertainingToRegulation30Restructuring contextRef="OneD">Acquisition (including agreement to acquire)</in-capmkt:EventOfAnnouncementPertainingToRegulation30Restructuring><in-capmkt:DateOfEventOfAnnouncementPertainingToRegulation30Restructuring contextRef="OneI">2025-05-27</in-capmkt:DateOfEventOfAnnouncementPertainingToRegulation30Restructuring><in-capmkt:DateOfReport contextRef="OneI">2025-05-28</in-capmkt:DateOfReport><in-capmkt:NameOfAcquirer contextRef="OneI">Entero Healthcare Solutions Limited</in-capmkt:NameOfAcquirer><in-capmkt:RelationshipOfAcquirerWithTheListedEntity contextRef="OneD">Listed Entity (self)</in-capmkt:RelationshipOfAcquirerWithTheListedEntity><in-capmkt:NameOfTheTargetEntity contextRef="OneI">Anand Medical Distributors</in-capmkt:NameOfTheTargetEntity><in-capmkt:TurnoverOfTargetEntity contextRef="OneD" decimals="-5" unitRef="INR">1915700000</in-capmkt:TurnoverOfTargetEntity><in-capmkt:ProfitAfterTaxOfTargetEntity contextRef="OneD" decimals="-5" unitRef="INR">34100000</in-capmkt:ProfitAfterTaxOfTargetEntity><in-capmkt:NetWorthOfTargetEntity contextRef="OneD" decimals="-5" unitRef="INR">50200000</in-capmkt:NetWorthOfTargetEntity><in-capmkt:WhetherTheAcquisitionWouldFallWithinRelatedPartyTransactions contextRef="OneD">false</in-capmkt:WhetherTheAcquisitionWouldFallWithinRelatedPartyTransactions><in-capmkt:WhetherAcquisitionEventRPTIsMaterial contextRef="OneD">false</in-capmkt:WhetherAcquisitionEventRPTIsMaterial><in-capmkt:WhetherThePromoterOrPromoterGroupOrGroupOrAssociateOrHoldingOrSubsidiaryCompaniesOrDirectorAndKMPAndItsRelativesHaveAnyInterestInTheEntityBeingAcquired contextRef="OneD">false</in-capmkt:WhetherThePromoterOrPromoterGroupOrGroupOrAssociateOrHoldingOrSubsidiaryCompaniesOrDirectorAndKMPAndItsRelativesHaveAnyInterestInTheEntityBeingAcquired><in-capmkt:WhetherAcquisitionIsDoneAtArmsLength contextRef="OneD">false</in-capmkt:WhetherAcquisitionIsDoneAtArmsLength><in-capmkt:IndustryToWhichTheEntityBeingAcquiredBelongs contextRef="OneI">Pharmaceutical</in-capmkt:IndustryToWhichTheEntityBeingAcquiredBelongs><in-capmkt:ObjectsAndEffectsOfAcquisitionIncludingButNotLimitedToDisclosureOfReasonsForAcquisitionOfTargetEntityIfItsBusinessIsOutsideTheMainLineOfBusinessOfTheListedEntity contextRef="OneI">The business of Anand Medical Distributors is in line of the business of the Company i.e. wholesale distribution of pharmaceutical and other allied products and the acquisition of business of Anand Medical Distributors by the Company shall enable the Company to generate additional business and revenue on consolidated basis</in-capmkt:ObjectsAndEffectsOfAcquisitionIncludingButNotLimitedToDisclosureOfReasonsForAcquisitionOfTargetEntityIfItsBusinessIsOutsideTheMainLineOfBusinessOfTheListedEntity><in-capmkt:WhetherAnyGovernmentalOrRegulatoryApprovalsRequiredForTheAcquisition contextRef="OneD">No</in-capmkt:WhetherAnyGovernmentalOrRegulatoryApprovalsRequiredForTheAcquisition><in-capmkt:WhetherTheAcquisitionTransactionWillBeInTranches contextRef="OneD">true</in-capmkt:WhetherTheAcquisitionTransactionWillBeInTranches><in-capmkt:IndicativeTimePeriodForCompletionOfTheAcquisition contextRef="OneI">15th August 2025</in-capmkt:IndicativeTimePeriodForCompletionOfTheAcquisition><in-capmkt:NatureOfConsiderationForAcquisitionEvent contextRef="OneD">Cash</in-capmkt:NatureOfConsiderationForAcquisitionEvent><in-capmkt:CostOfAcquisitionOrThePriceAtWhichTheSharesAreAcquired contextRef="OneD" decimals="-4" unitRef="INR">80000</in-capmkt:CostOfAcquisitionOrThePriceAtWhichTheSharesAreAcquired><in-capmkt:ExistingPercentageOfShareholdingHeldByAcquirer contextRef="OneI" decimals="INF" unitRef="pure">0</in-capmkt:ExistingPercentageOfShareholdingHeldByAcquirer><in-capmkt:PercentageOfControlAcquired contextRef="OneI" decimals="INF" unitRef="pure">0.8</in-capmkt:PercentageOfControlAcquired><in-capmkt:PercentageOfAdditionalSharesAcquiredIfExistingHoldingPersists contextRef="OneI" decimals="INF" unitRef="pure">0.8</in-capmkt:PercentageOfAdditionalSharesAcquiredIfExistingHoldingPersists><in-capmkt:BriefBackgroundAboutTheEntityAcquiredInTermsOfProductsLineOfBusinessAcquired contextRef="OneI">Anand Medical Distributors is engaged in the business of wholesale distribution of pharmaceutical and other allied products. 

The turnover of Anand Medical Distributors in financial year 2022-2023 is INR 1,365.59 Mn, for financial year 2023-24 is INR 1,661.54 Mn and for financial year 2024-25 is INR 1,924.61 Mn (9 months Annaulised).

Anand Medical Distributors conducts its business only in India.  

The Company has entered into a binding
Memorandum of Understanding for acquiring 80%
stake in Anand Medical Distributors, proprietorship
firm, through a proposed SPV to be formed, subject
to satisfactory completion of due diligence and
execution of definitive agreements and fulfilment of
conditions therein, if any.</in-capmkt:BriefBackgroundAboutTheEntityAcquiredInTermsOfProductsLineOfBusinessAcquired><in-capmkt:StartYearOfFirstPreviousYear contextRef="OneI">2024</in-capmkt:StartYearOfFirstPreviousYear><in-capmkt:EndYearOfFirstPreviousYear contextRef="OneI">2025</in-capmkt:EndYearOfFirstPreviousYear><in-capmkt:TurnoverOfFirstPreviousYear contextRef="OneD" decimals="-7" unitRef="INR">1920000000</in-capmkt:TurnoverOfFirstPreviousYear><in-capmkt:StartYearOfSecondPreviousYear contextRef="OneI">2023</in-capmkt:StartYearOfSecondPreviousYear><in-capmkt:EndYearOfSecondPreviousYear contextRef="OneI">2024</in-capmkt:EndYearOfSecondPreviousYear><in-capmkt:SecondPreviousYearTurnover contextRef="OneD" decimals="-7" unitRef="INR">1660000000</in-capmkt:SecondPreviousYearTurnover><in-capmkt:StartYearOfThirdPreviousYear contextRef="OneI">2022</in-capmkt:StartYearOfThirdPreviousYear><in-capmkt:EndYearOfThirdPreviousYear contextRef="OneI">2023</in-capmkt:EndYearOfThirdPreviousYear><in-capmkt:ThirdPreviousYearTurnover contextRef="OneD" decimals="-7" unitRef="INR">1370000000</in-capmkt:ThirdPreviousYearTurnover><in-capmkt:CountryInWhichTheAcquiredEntityHasPresence contextRef="OneI">India</in-capmkt:CountryInWhichTheAcquiredEntityHasPresence><in-capmkt:AnyOtherBriefSignificantInformationForTheAcquisition contextRef="OneI">8,000 equity shares of the proposed SPV will be
acquired at INR 10 (Indian Rupees Ten only) per
equity share at total amount of Rs. 80,000/- (Indian
Rupees Eighty Thousand only).</in-capmkt:AnyOtherBriefSignificantInformationForTheAcquisition></xbrli:xbrl>